Phlebitis due to intravenous administration of macrolide antibiotics. A comparative study of erythromycin versus clarithromycin;Flebitis relacionada con la administración intravenosa de antibióticos macrólidos. Estudio comparativo de eritromicina y claritromicina

Medicina Clinica

Volumn 116, Issue 4, 2001, Pages 133-135

  De García Díaz, Juan Dios ^a   Santolaya Perrín, Rosario ^a   Martínez Ortega, Ma Paz ^a   Moreno Vázquez, Margarita ^a  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Adverse reactions; Clarithromycin; Erythromycin; Macrolides; Phlebitis

Indexed keywords

ANTIBIOTIC AGENT; CLARITHROMYCIN; ERYTHROMYCIN; GLUCOCORTICOID; MACROLIDE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; HUMAN; INCIDENCE; MALE; PHLEBITIS; PNEUMONIA; RISK;

EID: 18844473686     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(01)71748-4     Document Type: Article

References (13)

1. Álvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 1999; 74: 613-634.
2. Marlin GE, Thompson PJ, Jenkins CR, Burgess KR, LaFranier DA. Study of serum levels, venous irritation and gastrointestinal side-effects with intravenous erythromycin lactobionate in patients with bronchopulmonary infection. Hum Toxicol 1983; 2: 593-605.
3. Putzi R, Blaser J, Luthy R, Wehrli R, Siegenthaler W. Side-effects due to intravenous infusion of erythromycin lactobionate. Infection 1983; 11: 161-163.
4. Charles L, Segreti J. Choosing the right macrolide antibiotic. A guide to selection. Drugs 1997; 53: 349-357.
5. Guay DR, Patterson DR, Seipman N, Craft JC. Overview of the torelability profile of clarithromycin in preclinical and clinical trials. Drugs Saf 1993; 8: 350-364.
6. Maki DG, Ringer M. Risk factors for infusion-related phlebitis with small peripheral venous catheters. A randomized controlled trial. Ann Intern Med 1991; 114: 845-854.
7. Martínez JA, Fernández P, Rodríguez E, Sobrino J, Torres M, Nubiola A et al. Cánulas intravenosas: complicaciones derivadas de su utilización y análisis de los factores predisponentes. Med Clin (Barc) 1994; 103: 89-93.
8. Ruiz-Laiglesia FJ, Torrubia-Pérez CB, Reclusa-Poyo F, Arnal-Rubio N. Flebitis en catéteres venosos periféricos. Med Clin (Barc) 1994; 103: 116-117.
9. Recio J, Alegre J, Len O, Fernández de Sevilla T. Flebitis en catéteres venosos periféricos. Med Clin (Barc) 1997; 108: 638-639.
10. Soifer NE, Borzak S, Edlin BR, Weinstein RA. Prevention of peripheral venous catheter complications with an intravenous therapy team: a randomized controlled trial. Arch Intern Med 1998; 158: 473-477.
11. Genne D, Siegrist HH, Humair L, Janin-Jaquat B, De Torrente A. Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1997; 16: 783-788.
12. Vetter N, Stamler D, O'Neill S, Rafferty P, Praz G, Durán Cantolla J et al. Claritromicina frente a la combinación de cefuroxima y eritromicina en el tratamiento de pacientes hospitalizados con neumonía adquirida en la comunidad: tratamiento intravenoso seguido del tratamiento oral. Clin Drug Invest (ed. esp.) 1997; 14: 439-450.
13. Monreal M, Quílez F, Rey-Joly C, Rodríguez S, Sopena N, Neira C et al. Infusion phlebitis in patients with acute pneumonia. Chest 1999; 115: 1576-1580.